A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

Prior treatment

• Patients who require administration of prohibited drugs during the clinical trial period after written informed consent
• Patients with any of the following criteria within 3 months before obtaining informed consent: myocardial infarction, severe or unstable angina pectoris, coronary angioplasty, coronary artery bypass surgery, stroke, transient ischemic attack, symptomatic carotid artery stenosis, symptomatic peripheral arterial disease, abdominal aortic aneurysm, uncontrolled severe arrhythmia and decompensated heart failure
• Patients with alcoholics or drug addicts
• Patients who participated in other clinical trials of a drug with new active ingredients within 16 weeks or a drug with an approved active ingredients within 12 weeks prior to administration and received an investigational drug other than placebo,or those who will participate in other clinical trials at the same time as the clinical trial

Other illness

• Patients with uncontrolled thyroid disease
• Patients with uncontrolled hypertension (SBP \>= 160 mmHg or DBP \>= 100 mmHg) at Screening
• Patients with heart failure class III or higher according to NYHA cardiac function classification
• Patients with malignant tumor or those who are judged to have a high risk of recurrence
• Patients with a history of myopathy or rhabdomyolysis due to K-877 (pemafibrate)
• Patients with a history of hypersensitivity due to K-877 (pemafibrate)
• Patients with a history of serious drug allergies (anaphylactic shock, etc.)

Lab values

• Patients with type 1 diabetes and uncontrolled diabetes \[HbA1c(NGSP) \>= 10.0 % at Screening\]
• Patients with an AST or ALT three times the upper limit at Screening
• Patients who have collected 400 mL or more of whole blood within 16 weeks, or 200 mL or more of whole blood within 4 weeks, or blood samples (plasma and platelet components) within 2 weeks before Screening

Other

• Patients with undergoing LDL apheresis
• Patients with cirrhosis or those with biliary obstruction
• Patients with familial hypercholesterolemia (homozygotes)
• Patients with an CK four times the upper limit at Screening
• Patients who plan to undergo PCI, CABG, carotid artery or peripheral revascularization
• Pregnant women, lactating women, women planning to become pregnant or lactating during the study period, or pregnant women\*2 who do not use specific contraceptive methods\*1
• Patients who have been determined inappropriate by the investigator, etc
  • 1 Acceptable contraceptive methods: oral, implantable/injectable contraceptive hormones, mechanical products \[intrauterine devices (IUDs) ,etc\] or barrier methods with spermicides (pessaries, condoms, cervical caps, etc)
  • 2 Woman of childbearing potential refers to a woman who is physiologically capable of becoming pregnant with a male partner who has not undergone contraception. However, it does not apply if the investigator confirms that any of the following criteria is met.
  • Patients with hysterectomy or tubal ligation before informed consent
  • Post-menopausal women (those who who have passed more than 1 year since their last menstrual period without other medical reasons).

• Patients had to be age 18 years or older at written informed consent
• Patients with statin intolerant hypercholesterolemia
• Patients who have laboratory records with fasting serum TG \<= 150 mg/dL (\<=175 mg/dL when not fasting) within 6 months prior to consent.
• Patients with the fasting serum TG \<= 150 mg/dL at screening
• Patients who have received dietary or exercise guidance from 12 weeks or more prior to Screening
• Patients who apply any of the following risk category with LDL-C level (Friedewald formula) based on JAS2022 at screening
  • Low risk for primary prevention: LDL-C \>=160 mg/dL
  • Intermediate risk for primary prevention: LDL-C \>=140 mg/dL
  • High risk for primary prevention: LDL-C\>=120 mg/dL
  • Secondary prevention: LDL-C\>=120 mg/dL